Clearstead Advisors, LLC Argenx Se Transaction History

Clearstead Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$532.27 - $656.65 $24,484 - $30,205	-46 Reduced 79.31%	12 $6,000
Q1 2025 May 13, 2025	SELL	$571.0 - $671.75 $13,704 - $16,122	-24 Reduced 29.27%	58 $34,000
Q4 2024 Feb 10, 2025	BUY	$520.52 - $638.33 $520 - $638	1 Added 1.23%	82 $50,000
Q2 2024 Aug 09, 2024	BUY	$356.01 - $451.55 $28,836 - $36,575	81 New	81 $34,000

525

26M

589K

320K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $50.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Clearstead Advisors, LLC with notifications on news.